UCLA has rights to the GBM patent pursuit too (it's not an executed patent). They're listed on it as well, as is Cognate. They pursued it based on preclinical DCVax-L +checkpoint data. When I did the search for the post, I did under Direct discussions but this CI patent has nothing to do with Direct.
COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor.
Bosch, Marnix Leo (Clyde Hill, WA, US) Ganjel, James Kelly (Bethesda, MD, US) Powers, Linda F. (Bethesda, MD, US) Liau, Linda M. (Los Angeles, CA, US) Prins, Robert M. (Pacific Palisades, CA, US)
COGNATE BIOSERVICES, INC. NORTHWEST BIOTHERAPEUTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA REVIMMUNE, INC.
But it makes me wonder how many other patents in their portfolio is not sole owned by NWBO. Is there really a reason to have NWBO patents owned by COI parties?
Market Data 
Markets 
AI
